The factor V Leiden mutation describes a guanine-to-adenine substitution at nucleotide
1691 that results in a glutamine instead of arginine at amino acid residue 506. Factor V …

Abstract Factor V Leiden (factor V Arg506Gln), the genetic defect underlying resistance to
activated protein C, is the most common risk factor for venous thrombosis. The relationship …

Oral contraceptive use in women with factor V Leiden is associated with increased rates of
venous thromboembolic events (VTEs). However, the effects of hormone replacement …

The cumulative thrombotic risk of Factor V (FV) Leiden and oral contraceptives (OC)
recommends screening for the mutation. Assuming that a family history of thrombosis …

Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to
activated protein C (APC) and an increased risk for venous thromboembolism (VTE). Deep …

It has been evident for over 30 years that combined oral contraceptive pills (OCP) increase
the risk of venous thromboembolism. Recently, it has been suggested that there is an …

Resistance to activated protein C (APC) is a common inherited risk factor for venous
thrombosis, which is associated with a mutation in coagulation factor V (factor V Leiden). We …

Factor V Leiden is a genetic disorder characterized by a poor anticoagulant response to
activated Protein C and an increased risk for venous thromboembolism. Deep venous …

Estrogen replacement therapy (ERT), which produces acquired resistance to activated
protein C when superimposed on heritable resistance to activated protein C (the mutant …

Several large-scale studies indicate that factor V Leiden (FVL) is not associated with an
increased risk of acute myocardial infarction (MI) in middle-aged or elderly populations. 1-7 …